Investors Recent News Apr 12, 2021 Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment Apr 01, 2021 Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer Mar 22, 2021 Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer View All Upcoming Events There are no upcoming events at this time. View All Past Events Mar 22, 2021 at 8:30 AM EDT DKN-01 Clinical Data Conference Call Supporting Materials DKN-01 Clinical Data Presentation 3.6 MB Mar 9 - Mar 10, 2021 H.C. Wainwright Global Life Sciences Conference Mar 1, 2021 at 10:00 AM EST Raymond James 42nd Annual Institutional Investors Conference View All
Apr 12, 2021 Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment
Apr 01, 2021 Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
Mar 22, 2021 Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer
Mar 22, 2021 at 8:30 AM EDT DKN-01 Clinical Data Conference Call Supporting Materials DKN-01 Clinical Data Presentation 3.6 MB
